Attard, G and Sydes, MR and Mason, MD and Clarke, NW and Aebersold, D and de Bono, JS and Dearnaley, DP and Parker, CC and Ritchie, AWS and Russell, JM and Thalmann, G and Cassoly, E and Millman, R and Matheson, D and Schiavone, F and Spears, MR and Parmar, MKB and James, ND
(2014)
Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial.
European Urology.
ISSN 0302-2838
DOI: https://doi.org/10.1016/j.eururo.2014.05.038
Abstract
There are compelling reasons to study the addition of both enzalutamide and abiraterone, in combination, to standard-of-care for hormone-naïve prostate cancer. Through a protocol amendment, this will be assessed in the STAMPEDE trial, with overall survival as primary outcome measure. © 2014 European Association of Urology.
More Information
Identification Number: | https://doi.org/10.1016/j.eururo.2014.05.038 |
---|---|
Status: | Published |
Refereed: | Yes |
Publisher: | Elsevier |
Date Deposited: | 16 Oct 2015 14:37 |
Last Modified: | 12 Jul 2024 09:55 |
Item Type: | Article |
Download
Export Citation
Explore Further
Read more research from the author(s):